News
MinervaX Raises EUR 54M in Upsized Financing to Advance the Development of its Maternal Vaccine Against Group B Streptococcus
New investment from EQT Life Sciences and OrbiMed with participation from existing investors MinervaX will hold financial reserves of more than €125 million, following the...
MinervaX Announces Completion of Enrolment in Phase 1 Clinical Vaccine Trial as it Addresses the Global Burden of Group B Streptococcus in Older Adults
Full enrolment and dosing commenced with its novel, prophylactic GBS vaccine in both healthy older adults and older adult population with co-morbidities First immunological...
MinervaX Commences First Phase 1 Clinical Study of Novel GBS Vaccine in Older Adults
Expands development of novel GBS vaccine in older adult population Targeting significant and growing unmet medical need of GBS infection Copenhagen, Denmark, 17 April 2023 –...
MinervaX appoints Lidia Oostvogels as Chief Medical Officer and provides clinical and regulatory update on its novel GBS vaccine
Newly appointed CMO with more than 25 years’ experience in vaccine development Fast Track status granted by US Food and Drug Administration Completion of enrolment of its 2nd...
MinervaX announces 72M EUR financing to advance development of novel vaccine against Group B Streptococcus
Financing from new investors Trill Impact Ventures and Pureos Bioventures as well as existing investors Backing from European Investment Bank Planning for Phase 3 clinical...
MinervaX announces that EMA has awarded PRIME Status for its Group B Streptococcal vaccine
Copenhagen, Denmark, 20 September 2022 – MinervaX, a privately held Danish biotechnology company today announces that EMA has awarded PRIME status for its vaccine against Group B...
MinervaX Provides Clinical Update on its Maternal GBS Vaccine
Completed enrolment of all pregnant women in a Phase 2 study in South Africa and UgandaFollowing clearance from the US FDA, Danish Medicines Agency and UK MRHA, started enrolment...
MinervaX provides clinical and leadership update
Completed enrolment of 150 pregnant women in a Phase 2 study in South Africa and dosing started in an additional 50 pregnant women in Uganda, as part of same studyPhase 1 booster...
MinervaX announces completion of 47.4 mEUR financing
MinervaX raises upsized EUR 47.4M (USD 57M) Series B to advance its novel Group B Streptococcus vaccine through mid-stage clinical trials On the back of highly promising Phase Ib...
